Creative Planning Acquires 27,289 Shares of Hims & Hers Health, Inc. $HIMS

Creative Planning raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 42.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 90,906 shares of the company’s stock after buying an additional 27,289 shares during the period. Creative Planning’s holdings in Hims & Hers Health were worth $4,532,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Nuveen LLC bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at about $58,403,000. CloudAlpha Capital Management Limited Hong Kong purchased a new position in Hims & Hers Health in the 1st quarter worth approximately $20,580,000. State of Michigan Retirement System lifted its position in Hims & Hers Health by 84.9% in the second quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock valued at $68,748,000 after purchasing an additional 633,300 shares during the last quarter. Jump Financial LLC boosted its stake in shares of Hims & Hers Health by 633.2% during the first quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock valued at $21,437,000 after purchasing an additional 626,496 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after purchasing an additional 397,310 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the completion of the transaction, the insider owned 297,139 shares of the company’s stock, valued at approximately $15,005,519.50. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total transaction of $6,852,231.96. Following the sale, the chief executive officer owned 160,425 shares in the company, valued at approximately $8,579,529. This trade represents a 44.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 630,583 shares of company stock worth $33,544,943. 13.71% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HIMS. BTIG Research reiterated a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday. UBS Group set a $32.00 target price on Hims & Hers Health in a research note on Tuesday, November 4th. Finally, KeyCorp started coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $34.71 on Friday. The company has a 50-day simple moving average of $49.10 and a two-hundred day simple moving average of $51.14. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm has a market capitalization of $7.90 billion, a PE ratio of 64.28, a price-to-earnings-growth ratio of 6.69 and a beta of 2.20. Hims & Hers Health, Inc. has a one year low of $23.03 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm’s revenue was up 49.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 EPS. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has authorized a share buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its shares are undervalued.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.